Results of a VHIO co-led retrospective study published in JCO Precision Oncology verify the use of diagnostic archival tissue biopsies…
featured news
Many of our Medical Oncologists and Clinical Investigators have just returned from presenting their latest data at the European Society…
The phase III international CheckMate 9ER trial continues to make headlines. Now published ahead of print in The Lancet Oncology…
The 12th Annual two-day WIN Symposium 2022, co-chaired by Richard L. Schilsky and our Director, Josep Tabernero, Chairman and Vice-Chairman…
The “J-BID – José Baselga Innovative Disruption Program” has an investment of up to 6 million euros and aims to…
For the first time in the context of brain metastasis, VHIO-led research has evidenced the striking preclinical efficacy of a…
HER2DX is the world’s first diagnostic test formulated specifically for HER2-positive (HER2+) breast cancer. HER2DX analyzes RNA on 27 genes…
For yet another year, researchers from the Vall d’Hebron Institute of Oncology (VHIO), which is part of the Vall d’Hebron…
